RXi Pharmaceuticals Corporation – Product Pipeline Review

Global Markets Direct’s, ‘RXi Pharmaceuticals Corporation – Product Pipeline Review – 2016’, provides an overview of the RXi Pharmaceuticals Corporation’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by RXi Pharmaceuticals Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of RXi Pharmaceuticals Corporation

The report provides overview of RXi Pharmaceuticals Corporation including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses RXi Pharmaceuticals Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features RXi Pharmaceuticals Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate RXi Pharmaceuticals Corporation’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for RXi Pharmaceuticals Corporation

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding RXi Pharmaceuticals Corporation’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

RXi Pharmaceuticals Corporation Snapshot 6

RXi Pharmaceuticals Corporation Overview 6

Key Information 6

Key Facts 6

RXi Pharmaceuticals Corporation - Research and Development Overview 7

Key Therapeutic Areas 7

RXi Pharmaceuticals Corporation - Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products - Monotherapy 11

RXi Pharmaceuticals Corporation - Pipeline Products Glance 12

RXi Pharmaceuticals Corporation - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Phase I Products/Combination Treatment Modalities 13

RXi Pharmaceuticals Corporation - Early Stage Pipeline Products 14

IND/CTA Filed Products/Combination Treatment Modalities 14

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

RXi Pharmaceuticals Corporation - Drug Profiles 17

diphencyprone 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

RXI-109 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

RNAi Oligonucleotide to Inhibit CTGF for PVR 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

RNAi Oligonucleotide Inhibiting MDM2 for Retinoblastoma 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

RNAi Oligonucleotide to Inhibit SOD-1 for ALS 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

RNAi Oligonucleotide to Inhibit VEGF for Macular Degeneration 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

RXI-209 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

bevasiranib sodium 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

MMP-26051 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

MMP-26052 29

Product Description 29

Mechanism of Action 29

R&D Progress 29

RNAi Oligonucleotide to Inhibit Angiopoietin-2 for Retinal Disease and Cancer 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Cancer 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

RNAi Oligonucleotides to Inhibit Complement C3 for Ophthalmology 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

RNAi Oligonucleotides to Inhibit TNF-alpha for Autoimmune Disorders 34

Product Description 34

Mechanism of Action 34

R&D Progress 34

TRY-26071 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

TRY-26077 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

RXi Pharmaceuticals Corporation - Pipeline Analysis 37

RXi Pharmaceuticals Corporation - Pipeline Products by Target 37

RXi Pharmaceuticals Corporation - Pipeline Products by Route of Administration 39

RXi Pharmaceuticals Corporation - Pipeline Products by Molecule Type 40

RXi Pharmaceuticals Corporation - Pipeline Products by Mechanism of Action 41

RXi Pharmaceuticals Corporation - Recent Pipeline Updates 43

RXi Pharmaceuticals Corporation - Dormant Projects 51

RXi Pharmaceuticals Corporation - Discontinued Pipeline Products 52

Discontinued Pipeline Product Profiles 52

bevasiranib sodium 52

RXi Pharmaceuticals Corporation - Locations And Subsidiaries 53

Head Office 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

List of Tables

RXi Pharmaceuticals Corporation, Key Information 6

RXi Pharmaceuticals Corporation, Key Facts 6

RXi Pharmaceuticals Corporation – Pipeline by Indication, 2016 8

RXi Pharmaceuticals Corporation – Pipeline by Stage of Development, 2016 10

RXi Pharmaceuticals Corporation – Monotherapy Products in Pipeline, 2016 11

RXi Pharmaceuticals Corporation – Phase II, 2016 12

RXi Pharmaceuticals Corporation – Phase I, 2016 13

RXi Pharmaceuticals Corporation – IND/CTA Filed, 2016 14

RXi Pharmaceuticals Corporation – Preclinical, 2016 15

RXi Pharmaceuticals Corporation – Discovery, 2016 16

RXi Pharmaceuticals Corporation – Pipeline by Target, 2016 37

RXi Pharmaceuticals Corporation – Pipeline by Route of Administration, 2016 39

RXi Pharmaceuticals Corporation – Pipeline by Molecule Type, 2016 40

RXi Pharmaceuticals Corporation – Pipeline Products by Mechanism of Action, 2016 41

RXi Pharmaceuticals Corporation – Recent Pipeline Updates, 2016 43

RXi Pharmaceuticals Corporation – Dormant Developmental Projects,2016 51

RXi Pharmaceuticals Corporation – Discontinued Pipeline Products, 2016 52

List of Figures

List of Figures

RXi Pharmaceuticals Corporation – Pipeline by Top 10 Indication, 2016 8

RXi Pharmaceuticals Corporation – Pipeline by Stage of Development, 2016 10

RXi Pharmaceuticals Corporation – Monotherapy Products in Pipeline, 2016 11

RXi Pharmaceuticals Corporation – Pipeline by Top 10 Target, 2016 37

RXi Pharmaceuticals Corporation – Pipeline by Route of Administration, 2016 39

RXi Pharmaceuticals Corporation – Pipeline by Molecule Type, 2016 40

RXi Pharmaceuticals Corporation – Pipeline Products by Top 10 Mechanism of Action, 2016 41

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports